The comparative effectiveness of treatments for obsessive-compulsive disorder

Bulletin of the Menninger Clinic

Volumn 62, Issue 4 SUPPL., 1998, Pages

  Greist, John H ^a,b,c  

^a Madison Institute of Medicine   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Healthcare Technology Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; CLINICAL TRIAL; COMPULSION; DRUG INDUCED DISEASE; HUMAN; MENTAL DISEASE; META ANALYSIS; NEUROSURGERY; OBSESSION; PSYCHOPHARMACOTHERAPY; REVIEW; SELF HELP;

BEHAVIOR THERAPY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031768005     PISSN: 00259284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Ananth, J., Burgoyne, K., Smith, M., & Swartz, R. (1995). Venlafaxine for treatment of obsessive-compulsive disorder [Letter to the editor]. American Journal of Psychiatry, 152, 1832.
3. Baer, L. (1991). Getting control. Boston: Little, Brown.
4. Baer, L., Rauch, S. L., Ballantine, H. T. Jr., Martuza, R., Cosgrove, R., Cassem, E., Giriunas, I., Manzo, P. A., Dimino, C., & Jenike, M. A. (1995). Cingulotomy for intractable obsessive-compulsive disorder: Prospective long-term follow-up of 18 patients. Archives of General Psychiatry, 52, 384-392.
5. Baxter, L. R., Schwartz, J. M., Bergman, K. S., Szuba, M. P., Guze, B. H., & Mazziotta, J. C. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry, 49, 681-689.
6. Bejerot, S., & Humble, M. (1991). Citalopram treatment of obsessive compulsive disorder: a pilot study of antiobsessive efficacy. Biological Psychiatry, 29, 443S.
7. Bisserbe, J. C., Lane, R. M., & Flament, M. F. (1997). A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. European Psychiatry, 12, 82-93.
8. Cartwright, C., & Hollander, E. (1997). Pharmacotherapy of obsessive-compulsive disorder-Experience with SSRIs. Primary Psychiatry, 4, 38, 41-45, 68.
9. Christensen, H., Hadzi-Pavlovic, D., Andrews, G., & Mattick, R. (1987). Behaviour therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: A quantitative review. Journal of Consulting and Clinical Psychology, 55, 701-711.
10. Cox, B. J., Swinson, R. P., Morrison, B., & Lee, P. S. (1993). Clomipramine, fluoxetine, and behaviour therapy in the treatment of obsessive-compulsive disorder: A meta-analysis. Journal of Behavior Therapy and Experimental Psychiatry, 24, 149-153.
11. DeVeaugh-Geiss, J., Katz, R., Landau, R., Akiskal, H., Ananth, J., Ballenger, J., Berts, W. C., Diamond, B., Feiger, A., Foa, E., Fogelson, D., Goodman, W., Greist, J., Himmelhoch, J., Hoehn-Saric, R., Jenike, M., Kim, S. W., Liebowitz, M., Mavissakalian, M., Ninan, P., Noyes, R., Rasmussen, S., Ringold, A., & Shear, K. (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder: The clomipramine collaborative study group. Archives of General Psychiatry, 48, 730-738.
12. Eisenberg, J., & Asnis, G. (1985). Lithium as an adjunct treatment in obsessive-compulsive disorder. American Journal of Psychiatry, 142, 663.
13. Erzegovesi, S., Ronchi, P., & Smeraldi, E. (1992). 5HT-2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacology, 7, 287-289.
14. Feder, R. (1988). Lithium augmentation of clomipramine. Journal of Clinical Psychiatry, 49, 458.
15. Foa, E. B., & Kozak, M. J. (1996). Psychological treatment for obsessive-compulsive disorder. In M. R. Mavissakalian & R. F. Pruen (Eds.), Long-term treatments of anxiety disorders (pp. 265-309). Washington, DC: American Psychiatric Press.
16. Foa, E. B., Kozak, M. J., Goodman, W. K., Hollander, E., Jenike, M. A., & Rasmussen, S. A. (1995). DSM-IV field trial: Obsessive-compulsive disorder. American Journal of Psychiatry, 152, 90-96.
17. Foa, E. B., Steketee, G. S., & Ozarow, B. J. (1985). Behaviour therapy with obsessive-compulsives: From theory to treatment. In M. Mavissakalian, S. M. Turner, & L. Michelson (Eds.), Obsessive-compulsive disorder: Psychological and pharmacological treatment (pp. 49-129). New York: Plenum.
18. Foa, E. B., & Wilson, R. (1991). Stop obsessing! New York: Bantam.
19. Goisman, R. M., Rogers, M. P., Steketee, G. S., Warshaw, M. G., Cuneo, P., & Keller, M. B. (1993). Utilization of behavioral methods in a multicenter anxiety disorders study. Journal of Clinical Psychiatry, 54, 213-218.
20. Golden, R. N., Morris, J. E., & Sack, D. A. (1988). Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biological Psychiatry, 23, 181-185.
21. Goodman, W. K., Price, L. H., Delgado, P. L., Palumbo, J., Krystal, J. H., Nagy, L. M., Rasmussen, S. A., Heninger, G. R., & Charney, D. S. (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Comparison of fluvoxamine and desipramine. Archives of General Psychiatry, 47, 577-585.
22. Grady, T. A., Pigott, T. A., L'Heureux, F., Hill, J. L., Bernstein, S. E., & Murphy, D. L. (1993). Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. American Journal of Psychiatry, 150, 819-821.
23. Greist, J. (1989). Computer-administered behaviour therapies. International Review of Psychiatry, 1, 267-274.
24. Greist, J. (1996). New developments in behaviour therapy for obsessive-compulsive disorder. International Clinical Psychopharmacology, 11, 63-73.
25. Greist, J. (1997). Obsessive-compulsive disorder: A guide (rev. ed.). Madison, WI: Dean Foundation Information Centers.
26. Greist, J., Chouindard, G., Duboff, E., Halaris, A., Kim, S. W., Koran, L., Liebowitz, M., Lydiard, R. B., Rasmussen, S., White, K., & Sikes, C. (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry, 52, 289-295.
27. Greist, J. H., Jefferson, J. W., Kobak, K. A., Katzelnick, D. J., & Serlin, R. C. (1995). Efficacy and tolerabiliry of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Archives of General Psychiatry, 52, 53-60.
28. Greist, J. H., Marks, I. M., Baer, L., Parkin, J. R., Manzo, P. A., Mantle, J. M., Wenzel, K. W., Spierings, C. J., Kobak, K. A., Dottl, S. L., Bailey, T. M., & Forman, L. (1998). Self-treatment for obsessive compulsive disorder using a manual and a computerized telephone interview: A U.S.-U.K. study. MD Computing, 75, 149-157.
29. Grossman, R., & Hollander, E. (1996). Treatment of obsessive-compulsive disorder with venlafaxine. American Journal of Psychiatry, 153, 576-577.
30. Hay, P., Sachdev, P., Cumming S., Smith, J. S., Lee, T., Kitchener, P., & Matheson, J. (1993). Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatrica Scandinavica, 87, 197-207.
31. Hewlett, W. A., Vinogradov, S., & Agras, W. S. (1992). Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12, 420-430.
32. Jacobsen, F. M. (1995). Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Journal of Clinical Psychiatry, 56, 423-429.
33. Jenike, M. A., Baer, L., & Minichiello, W. E. (1990). Obsessive-compulsive disorders: Theory and management (2nd ed.). Chicago: Year Book Medical Publishers.
34. Jenike, M. A., Baer, L., Minichiello, W. E., Rauch, S. L., & Buttolph, M. L. (1997). Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. American Journal of Psychiatry, 154, 1261-1264.
35. Joel, S. W. (1959). Twenty month study of iproniazid therapy. Diseases of the Nervous System, 20, 14.
36. Joffe, R. T., & Swinson, R. P. (1990). Tranylcypromine in primary obsessive-compulsive disorder. Journal of Anxiety Disorders, 4, 365-367.
37. Karno, M., Golding, J. M., Sorenson, S. B., & Burnam, M. A. (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Archives of General Psychiatry, 45, 1094-1099.
38. Kobak, K. A. (1995). Behavioral versus pharmacological treatment of obsessive-compulsive disorder: A meta-analysis. Unpublished doctoral dissertation. University of Wisconsin, Madison.
39. Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998). Behavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis. Psychopharmacology, 136, 205-216.
40. Kohen, D. P. (1996). Hypnotherapeutic management of pediatric and adolescent trichotillomania. Journal of Developmental and Behavioral Pediatrics, 17, 328-334.
41. Koponen, H., Lepola, U., Leinonen, E., Jokinen, R., Penttinen, J., & Turtonen, J. (1997). Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiatrica Scandinavica, 96, 343-346.
42. Koran, L. M., McElroy, S. L., Davidson, J. R. T., Rasmussen, S. A., Hollander, E., & Jenike, M. A. (1996). Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. Journal of Clinical Psychopharmacology, 16, 121-129.
43. Lipsedge, M. S., & Prothero, W. (1987). Clonidine and clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry, 144, 965-966.
44. Lopez-Ibor, J. J., Jr., Saiz, J., Cottraux, J., Note, I., Vinas, R., Bourgeois, M., Hernandez, M., & Gomez-Pérez, J. C. (1996). Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. European Neuropsychopharmacohgy, 6, 111-118.
45. Lucey, J. V., Butcher F., Clare, A. W., & Dinan, T. D. (1994). The clinical characteristics of patients with obsessive-compulsive disorder: A descriptive study of an Irish sample. Irish Journal of Psychological Medicine, 11, 11-14.
46. March, J. S., Frances, A., Carpenter, D., & Kahn, D. A. (1997). The expert consensus panel for obsessive-compulsive disorder: Treatment of obsessive compulsive disorder. Journal of Clinical Psychiatry, 58(Suppl. 4), 1-72.
47. March, J. S., Mulle, K., & Harbel, B. (1994). Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: An open trial of a new protocol-driven treatment package. Journal of the American Academy of Child Psychiatry, 33, 333-341.
48. Markovitz, P. J., Stagno, S. J., & Calabrese, J. R. (1990). Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. American Journal of Psychiatry, 147, 798-800.
49. Marks, I. M. (1978). Living with fear. New York: McGraw-Hill.
50. Marks, I. M., Baer, L., Greist, J. H., Park, J. M., Bachofen, M., Nakagawa, A., Wenzel, K. W., Parkin, J. R., Manzo, P. A., Dottl, S. L., & Mantle, J. M. (1998). Home self-assessment of obsessive-compulsive disorder: Use of a manual and a computer-conducted telephone. British Journal of Psychiatry, 172, 406-412.
51. Marks, I. M., Hodgson, R., & Rachman, S. (1975). Treatment of chronic obsessive-compulsive neurosis in vivo exposure: A 2-year follow-up and issues in treatment. British Journal of Psychiatry, 127, 349-364.
52. Marks, I. M., Lelliott, P., Basoglu, M., Noshirvani, H., Monteiro, W., Cohen, D., & Kasvikis, Y. (1988). Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 152, 522-534.
53. Marks, I. M., Stern, R. S., Mawson, D., Cobb, J., & McDonald, R. (1980). Clomipramine and exposure for obsessive-compulsive rituals: I. British Journal of Psychiatry, 136, 1-25.
54. McDonald, R., Marks, I. M., & Blizard, R. (1988). Quality assurance of outcome in mental health care: A model for routine use in clinical settings. Health Trends, 20, 111-114.
55. McDougle, C. J., Goodman, W. K., Leckman, J. F., Holzer, J. C., Barr, L. C., McCance-Katz, E., Heninger, G. R., & Price, L. H. (1993). Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 150, 647-649.
56. McDougle, C. J., Goodman, W. K., Leckman, J. F., Lee, N. C., Heninger, G. R., & Price, L. H. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 52, 302-308.
57. McDougle, D. J., Price, L. H., Goodman, W. K., Charney, D. S., & Heninger, G. R. (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy. Journal of Clinical Psychopharmacology, 11, 175-184.
58. Meyer, V. (1966). Modification of expectations in cases with obsessional rituals. Behaviour Research and Therapy, 4, 273-280.
59. Mindus, P., & Jenike, M. A. (1992). Neurosurgical treatment of malignant obsessive compulsive disorder. Psychiatric Clinics of North America, 15, 921-938.
60. Mundo, E., Bianchi, L., & Bellodi, L. (1997). Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study. Journal of Clinical Psychopharmacology, 17, 267-271.
61. Nelson, E. C. (1994). An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder. Annals of Clinical Psychiatry, 6, 249-253.
62. Neziroglu, F., & Yaryura-Tobias, J. A. (1991). Over and over again: understanding obsessive-compulsive disorder. Lexington, MA: Lexington Books.
63. Orloff, L. M., Battle, M. A., Baer, L., Ivanjack, L., Pettit, A. R., Buttolph, M. L., & Jenike, M. A. (1994). Long-term follow-up of 85 patients with obsessive-compulsive disorder. American Journal of Psychiatry, 251, 441-442.
64. O'Sullivan, G., Noshirvani, H., Marks, I., Monteiro, W., & Lelliott, P. (1991). Six-year follow-up after exposure and clomipramine therapy for obsessive-compulsive disorder. Journal of Clinical Psychiatry, 52, 150-155.
65. Pato, M. T., Hill, J. L., & Murphy, D. L. (1990). A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacology Bulletin, 26, 211-214.
66. Pato, M. T., Murphy, D. L., & De Vane, C. L. (1991). Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. Journal of Clinical Psychopharmacology, 11, 224-225.
67. Peabody, F. W. (1927). The care of the patient. Journal of the American Medical Association, 88, 877-882.
68. Piccinelli, M., Pini, S., Bellantuono, C, & Wilkinson, G. (1995). Efficacy of drug treatment in obsessive-compulsive disorder: A meta-analytic review. British Journal of Psychiatry, 166, 424-443.
69. Pigott, T. A., L'Heureux, F., Hill, J. L., Bihari, K., Bernstein, S. E., & Murphy, D. L. (1992). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12, 11-18.
70. Pigott, T. A., Pato, M. T., L'Heureux, F., Hill, J. L., Grover, G. N., Bernstein, S. E., & Murphy, D. L. (1991). A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 11, 242-248.
71. Rasmussen, S. A. (1984). Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. American Journal of Psychiatry, 141, 1283-1285.
72. Rasmussen, S. A., & Eisen, J. L. (1988). Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psychopharmacology Bulletin, 24, 466-470.
73. Rasmussen, S. A., Goodman, W. K., Greist, J. H., Jenike, M. A., Kozak, M. J., Liebowitz, M., Robinson, D. G., & White, K. L. (in press). Fluvoxamine in the treatment of obsessive-compulsive disorder: A multi-center double-blind placebo-controlled study in outpatients. American Journal of Psychiatry.
74. Rasmussen, S. A., & Tsuang, M. T. (1984). The epidemiology of obsessive compulsive disorder. Journal of Clinical Psychiatry, 45, 450-457.
75. Rauch, S. L., & Jenike, M. A. (1997). Neural mechanisms of obsessive-compulsive disorder. Current Review of Mood and Anxiety Disorders, 1, 84-94.
76. Rauch, S. L., O'Sullivan, R. L., & Jenike, M. A. (1996). Open treatment of obsessive-compulsive disorder with venlafaxine: A series of ten cases. Journal of Clinical Psychopharmacology, 16, 81-84.
77. Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., & Maina, G. (1996). Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacology Bulletin, 32, 167-173.
78. 3 receptor and antiobsessional effect. Human Psychopharmacology, 7, 291-292.
79. Stein, D. J., Spadaccini, E., & Hollander, E. (1995). Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. International Clinical Psychopharmacology, 70, 11-18.
80. Steketee, G. S., & White, K. (1990). When once is not enough. New York: Guilford.
81. Thomsen, P. H. (1997). Child and adolescent obsessive-compulsive disorder treated with citalopram: Findings from an open trial of 23 cases. Journal of Child and Adolescent Psychopharmacology, 7, 157-166.
82. Thorén, P., Åsberg, M., Bertilsson, L., Mellström, B., Sjöqvist, F., & Träskman, L. (1980). Clomipramine treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 37, 1289-1294.
83. Tollefson, G. D., Rampey, A. H., Jr., Potvin, J. H., Jenike, M. A., Rush, A. J., Dominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W., & Genduso, L. A. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 57, 559-567.
84. Vallejo, J., Olivares, J., Marcos, T., Bulbena, A., & Mechon, J. M. (1992). Clomipramine versus phenelzine in obsessive-compulsive disorder: A controlled clinical trial. British Journal of Psychiatry, 161, 665-670.
85. van Balkom, A. J. L. M., van Oppen, P., Vermeulen, A. W. A., van Dyck, R., Nauta, M. C. E., & Vorst, H. C. M. (1994). A meta-analysis on the treatment of obsessive-compulsive disorder: A comparison of antidepressants, behaviour, and cognitive therapy. Clinical Psychological Review, 74, 359-381.
86. van Dyck, R. (1995). Meta-analysis of the treatment of obsessive-compulsive disorder [abstract]. In 1st International Congress on Education and Progress in OCD, June 22-25, 1995. Barcelona, Spain (p. 23). Egham, Surrey, England: Medical Action Communications.
87. van Oppen, P., De Haan, E., van Balkom, A. J. L. M., Spinhoven, P., Hoogduin, K., & van Dyck, R. (1995). Cognitive therapy and exposure in vivo in the treatment of obsessive-compulsive disorder. Behaviour Research Therapy, 33, 379-390.
88. van Renynghe de Voxvrie, G. (1968). Use of anafranil (G 34586) in obsessive neuroses. Acta Neurologica Belgica, 68, 787-792.
89. Wever, C., & Rey, J. M. (1997). Juvenile obsessive-compulsive disorder. Australian Journal of Psychiatry, 31, 105-113.
90. Wheadon, D. E., Bushnell, W. D., & Stein, M. (1993, December). A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. In Abstracts of panels and posters presented at the annual meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii. Nashville: Vanderbilt University.
91. Yaryura-Tobias, J. A., & Neziroglu, F. A. (1996). Venlafaxine in obsessive-compulsive disorder. Archives of General Psychiatry, 53, 653-654.
92. Zajecka, J. M., Fawcett, J., & Guy, C. (1990). Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. Journal of Clinical Psychopharmacology, 10, 152-153.
93. Zohar, J., Zohar-Kodouch, R. C., & Kindler, S. (1992). Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs, 43, 210-218.